Clinical relevance of thymic and bone marrow outputs in multiple sclerosis patients treated with alemtuzumab. Sottini A, Quaresima V, Barbaro M, Moiola L, et al. J Neuroimmunol 2023;382:578170.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Sottini A, Quaresima V, Barbaro M, Moiola L, et al. Clinical relevance of thymic and bone marrow outputs in multiple sclerosis patients treated with alemtuzumab. J Neuroimmunol 2023;382:578170.
PMID: 37579546